Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening (Q83769773)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

title

Identification of diverse dipeptidyl peptidase IV inhibitors via structure-based virtual screening (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

5

Xu Shen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Cui Li

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Weiqiang Lu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Chunhua Lu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Wen Xiao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Guixia Liu

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

Yun Tang

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

30 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

Journal of Molecular Modeling

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

4033-4042

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00894-012-1394-3

27 January 2020

exact match

0 references

cites work

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

1 reference

12 December 2020

The design of potent and selective inhibitors of DPP-4: optimization of ADME properties by amide replacements

1 reference

12 December 2020

Two highly conserved glutamic acid residues in the predicted β propeller domain of dipeptidyl peptidase IV are required for its enzyme activity

1 reference

12 December 2020

Design, synthesis, and biological evaluation of triazolopiperazine-based beta-amino amides as potent, orally active dipeptidyl peptidase IV (DPP-4) inhibitors

1 reference

12 December 2020

Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors

1 reference

12 December 2020

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes

1 reference

12 December 2020

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

12 December 2020

(3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

1 reference

12 December 2020

Imidazopiperidine amides as dipeptidyl peptidase IV inhibitors for the treatment of diabetes

1 reference

12 December 2020

A three-dimensional pharmacophore model for dipeptidyl peptidase IV inhibitors.

1 reference

12 December 2020

Identification of the active site residues in dipeptidyl peptidase IV by affinity labeling and site-directed mutagenesis

1 reference

12 December 2020

Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV

1 reference

12 December 2020

Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin

1 reference

12 December 2020

3D-QSAR studies on fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA

1 reference

12 December 2020

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-dipeptidyl peptidase IV (CD26) included in a subgroup of serine proteases

1 reference

12 December 2020

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

1 reference

12 December 2020

Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes

1 reference

12 December 2020

Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibitors for the treatment of diabetes

1 reference

12 December 2020

Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design

1 reference

12 December 2020

(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor

1 reference

12 December 2020

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

12 December 2020

Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines

1 reference

12 December 2020

Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes

1 reference

12 December 2020

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).

1 reference

12 December 2020

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

12 December 2020

(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

1 reference

12 December 2020

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

1 reference

12 December 2020

Discovery of beta-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV.

1 reference

12 December 2020

(2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

12 December 2020

Tyrosine 547 constitutes an essential part of the catalytic mechanism of dipeptidyl peptidase IV.

1 reference

12 December 2020

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

1 reference

12 December 2020

4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV

1 reference

12 December 2020

10.1007/S00894-012-1394-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22460522%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference